ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTRS

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Viatris securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by June 3, 2025, to serve as lead plaintiff [2] - The lawsuit alleges that Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the impact of an FDA Warning Letter that restricted shipments of eleven products [4][5] Group 2: Misleading Statements - Defendants allegedly made materially false statements and concealed adverse facts about the financial impact of the FDA Warning Letter on Viatris [5] - The lawsuit claims that the lack of disclosure regarding the inspection timeline, remediation efforts, and the financial implications led to investors purchasing securities at artificially inflated prices [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [3]